Replies to post #2464 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

MDACC will present just don't know where or at how many venues. We just have to round up the usual suspects but my money is on AACR and/or ASCO and/or WCLC. If Spectrum announces top line before WCLC, I could see presenting Zenith 20 egfr data there.

IASLC 2019 TARGETED THERAPIES OF LUNG CANCER MEETING
February 20 - 23 2019 | Santa Monica, California

GOAL AND PURPOSE:
This IASLC-sponsored meeting is designed to provide information about ongoing clinical trials of the newest therapies for lung cancer. The meeting presenters summarize the data on relevant targets for new therapies. Data on preclinical and early clinical data are presented for each of the drugs directed against these targets. The meeting also presents data on early predictive biomarkers. There are also presentations from fellows and young investigators in training and debates about controversial topics. The meeting is a unique resource for clinical investigators, including those in academia, clinical practice and industry.

EUROPEAN LUNG CANCER CONGRESS 2019 (#ELCC19)
April 10 - 13 2019 | Geneva, Switzerland

The European Lung Cancer Congress (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
ELCC is now the point of reference in the field of thoracic malignancies. Since its inaugural edition in 2008, it has secured its status as the premier meeting for professionals in the field.
Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.

IASLC 20TH WORLD CONFERENCE ON LUNG CANCER (#WCLC19)
September 7 - 10 2019 | Barcelona, Spain
GOAL AND PURPOSE:
The IASLC 20th World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries come to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients. The conference also offers incredible opportunities for networking and collaboration.

AACR (Mar 29 – Apr 3)

ASCO (May 31 – June 4)